CYP450 Inhibitors
1 drugsAbout CYP450
Cytochrome P450 enzymes (CYP450) are heme-containing monooxygenases that metabolize endogenous and exogenous compounds. Primarily located in the liver, they play a key role in drug metabolism, influencing drug efficacy and toxicity.
CYP450's impact on drug response makes it a relevant target in drug development, though no genetic evidence currently links CYP450 variations directly to specific diseases.
CYP450 is targeted by one FDA-approved drug, SPORANOX (Johnson & Johnson), a small molecule with applications classified as 'Other'. SPORANOX was first approved in 1992.
Top CYP450 Drugs
Johnson & Johnson is the only company with an approved drug targeting CYP450.
Low competition may indicate high barriers to entry or limited market potential, requiring careful evaluation.
CYP450 Clinical Trials 414 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on CYP450. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 364 | 297 | 17 | 50 | 95% |
| Phase 2 | 26 | 13 | 7 | 6 | 65% |
| Phase 3 | 9 | 4 | 0 | 5 | 100% |
| Phase 4 | 15 | 6 | 4 | 5 | 60% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 198 (152 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on CYP450. A trial counts if an approved drug acting on CYP450 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.